home.aspx
 
EVENTS

Highly Potent Active Pharmaceuticals Ingredients
HIGHLY POTENT ACTIVE PHARMACEUTICALS INGREDIENTS
October 21-22, 2019
SMi is delighted to announce its Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21st - 22nd October 2019. The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segmen...

HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS USA
HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS USA
October 21-22, 2019
The event will explore how the latest technologies can benefit HPAPI with artificial intelligence and machine learning to hasten risk assessment and validation.

Uberflip

Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

RELATED NEWS


Sanofi, Novo Nordisk, and Eli Lilly have faced years of scrutiny over insulin prices, but their responses haven't satisfied two Democratic lawmakers who this week kicked off a fresh investigation into pricing for the products. The probe comes as drug pricing creates daily headlines in Washington, D.C., with lawmakers on both sides of the aisle debating potential solutions. Reps. Frank Pallone, chair of the House Energy and Commerce Committee, and Diana DeGette, chair of the Oversight and Inv...

READ MORE

Medicare and its beneficiaries could have saved an estimated $17.7 billion over a seven-year period on generic versions of older medicines instead of paying for newer, chemically similar but more expensive brand-name drugs, according to a study published in the Annals of Internal Medicine last month. The study was conducted as part of the Collaboration for Research Integrity and Transparency at Yale Law School, funded by the Laura and John Arnold Foundation. The intent was to estimate the potent...

READ MORE

CaPre is a potentially best-in-class omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia,a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis....

READ MORE

BlackRock Advisors LLC reduced its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 98.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 358,973 shares of the company’s stock after selling 27,783,688 shares during the period. BlackRock Advisors LLC owned about 0.21% of BioMarin Pharmaceutical worth $33,213,000 at the end of the most recent quarter....
THECERBATGEM.COM
READ MORE

Pfizer is a big company with a diverse portfolio, but it hasn’t really been noted for its presence in the oncology market. The majority of its successful drugs are in primary care and heart medicine, like Lipitor (atorvastatin) for cholesterol, Lyrica (pregabalin) for neuropathic pain and fibromyalgia, Zithromax (azithromycin), an antibiotic, and Viagra (sildenafil) for erectile dysfunction. But now, Pfizer offers 17 drugs to treat cancer, with four approved in the U.S. in 2017. The oncolo...

READ MORE

Amgen’s osteoporosis bone-forming drug Evening (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the US market in 2017, but the FDA rejected it after picking up on an unexpectedly high incidence of cardiovascular events in one of the two phases 3 trials in the company’s first filing. Developed in partnership with Belgium’s UCB, the companies refiled the drug with the FDA last summer wi...

READ MORE

EVENTS

Highly Potent Active Pharmaceuticals Ingredients
HIGHLY POTENT ACTIVE PHARMACEUTICALS INGREDIENTS
October 21-22, 2019
SMi is delighted to announce its Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21st - 22nd October 2019. The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segmen...

30th International Nursing and Primary Healthcare Professionals Congress
30TH INTERNATIONAL NURSING AND PRIMARY HEALTHCARE PROFESSIONALS CONGRESS
October 21-22, 2019
Nursing-PHC 2019 is an excellent opportunity for healthcare providers to authenticate and improve clinical experiences, acquire new management skills, network with experts from around the world, learn about new services, products and advances in the fields of Nursing and Primary Health Care. The con...